Minapharm Pharmaceuticals results, Q1 2025
Net profit, assets, equity and cash flow for Q1 2025, against the same period a year earlier, from the published financial statements.
Net profit-1.96 millionEGP · −148.3% vs the same period a year earlier
Total assets12.31 billionEGP · +10.8% vs the same period a year earlier
Shareholders' equity4.57 billionEGP · +9.0% vs the same period a year earlier
Operating cash flow-76.52 millionEGP · −157.8% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Q1 2025 was about -1.96 million EGP, down −148.3% from 4.05 million EGP in Q1 2024.
- Total assets at the end of Q1 2025 were about 12.31 billion EGP, and shareholders' equity about 4.57 billion EGP.
- Operating cash flow for Q1 2025 was negative at 76.52 million EGP.
Key lines against the same period a year earlier
This periodQ1 2024Change
Net profit-1.96 million4.05 million−148.3%
Gross profit646 million273 million+137.0%
Total assets12.31 billion11.11 billion+10.8%
Total liabilities7.74 billion6.92 billion+11.9%
Shareholders' equity4.57 billion4.19 billion+9.0%
Total liabilities and equity12.31 billion11.11 billion+10.8%
Operating cash flow-76.52 million132 million−157.8%
Investing cash flow-143 million-177 million+19.3%
Financing cash flow-7.37 million1.45 billion−100.5%
Net change in cash-226 million1.41 billion−116.1%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy